Synedgen Welcomes Dr. Laura Saward as New Chief Scientific Officer
Synedgen Welcomes Dr. Laura Saward as Chief Scientific Officer
Synedgen, Inc. has recently made an exciting announcement regarding its team, revealing that Dr. Laura Saward, PhD, will be stepping into the role of Chief Scientific Officer. Synedgen, a biotechnology firm focused on human glycobiology for treating gastrointestinal diseases, is keen on advancing its scientific endeavors with her leadership.
Dr. Saward's Impressive Background
With a strong background spanning over 25 years in therapeutic drug development, Dr. Saward brings a wealth of experience to Synedgen. She has successfully navigated the intricate process from preclinical studies through to drug licensure. Her proven track record in managing significant government contracts makes her a valuable asset in steering the company's research initiatives.
Insights from Dr. Gregory
Dr. Kenton Gregory, Chairman of the Board of Directors at Synedgen, expressed enthusiasm about Dr. Saward's appointment. He emphasized her substantial knowledge in drug development and the strategic importance of her role soon after Synedgen’s recent partnership with the Biomedical Advanced Research and Development Authority, valued up to $119 million. This collaboration aims to support their primary drug candidate MIIST305, focused on treating gastrointestinal acute radiation syndrome and ulcerative colitis.
Dr. Saward's Vision
Expressing her excitement about joining Synedgen, Dr. Saward stated her intent to utilize her scientific expertise to propel the development of MIIST305. This drug candidate holds significant promise, and Dr. Saward recognizes the potential benefits it can offer. She underscored the unique technological advancements that Synedgen possesses, relevant to both biodefense and commercial fields, especially with the backing of recent partnerships.
Previous Experience Enhancing Success
Before Synedgen, Dr. Saward served as Executive Vice President for Health and Medical at Adva Diagnostics Inc., where she played a pivotal role in formulating strategies aimed at business growth and expanding partnerships. Her tenure also includes various executive positions with Emergent BioSolutions, where she led the Therapeutics Business Unit, demonstrating her capability in driving projects to fruition.
Within Cangene, she held multiple leadership roles, including Chief Scientific Officer, contributing to the successful licensing of numerous products for both governmental and commercial entities. Dr. Saward’s background provides a solid foundation for her new responsibilities at Synedgen.
Academic Foundations and Ongoing Contributions
Dr. Saward began her academic journey with a Bachelor of Science from the University of Guelph, followed by obtaining her PhD from the University of Manitoba's Faculty of Medicine. She continues to engage with the academic community as an adjunct professor at the University of Manitoba, where she contributes to the Department of Medical Microbiology and Infectious Diseases. Her involvement with various boards further highlights her commitment to fostering knowledge and innovation within the field.
About Synedgen
Synedgen, Inc. is at the forefront of biotechnology, specializing in the development of Multivalent Innate Immune Signaling Target (MIIST) therapeutics designed to enhance the innate immune response. They are particularly focused on MIIST305, an oral therapy targeted for the induction and maintenance of ulcerative colitis. Additionally, MIIST305 is concurrently advancing as a medical countermeasure for gastrointestinal acute radiation syndrome, showcasing the dual utility of the therapy.
With substantial support from the US Government, MIIST technology has been validated through numerous clinical trials and is backed by extensive funding from twenty-two National Institutes of Health grants and Department of Defense contracts. Synedgen also boasts an in-house GMP manufacturing facility, emphasizing its capability to deliver innovative solutions to pressing medical challenges.
Frequently Asked Questions
Who is Dr. Laura Saward?
Dr. Laura Saward is a biotechnology executive with over 25 years of experience in therapeutic drug development.
What position has Dr. Saward been appointed to at Synedgen?
Dr. Saward has been appointed as the Chief Scientific Officer at Synedgen.
What is MIIST305?
MIIST305 is Synedgen's lead drug candidate, targeting ulcerative colitis and gastrointestinal acute radiation syndrome.
What are Synedgen's main focus areas?
Synedgen focuses on glycobiology and developing therapeutics to enhance the innate immune system.
What experience does Dr. Saward bring?
Dr. Saward has extensive experience in drug development and managing government contracts from her previous roles.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
